Wilson Therapeutics Strengthens its Board of Directors by the Appointments of Birgitte Volck and Björn OdlanderMay 22, 2017
The Annual General Meeting of Wilson Therapeutics AB (publ), has elected Dr. Birgitte Volck and Dr. Björn Odlander as new members of the Board of Directors.
Dr. Birgitte Volck is Senior Vice President, Head of R&D Rare Disease at GlaxoSmithKline headquarters in London, UK. Dr. Volck has extensive development experience with orphan drugs and more than 17 years of experience from senior roles in the biotech industry. Prior to GlaxoSmithKline, Dr. Volck served as Chief Medical Officer and Head of Development at Sobi and has also held senior roles at Amgen, Genzyme and Pharmexa. Throughout her industry career, Dr. Volck has led early and late stage development programs and executed product commercialization and regulatory strategies, particularly for new medicines in the orphan space. She holds a medical degree and a PhD from Copenhagen University in Denmark.
Dr. Volck stated: “I am passionate about bringing new treatment options to patients with rare diseases and I am pleased to be invited to work with a company that shares this vision. This is an important time for Wilson Therapeutics as it embarks on a pivotal study for WTX101 and begins to build its commercial expertise. I am looking forward to engaging with the board of directors and imparting the knowledge I have gained through many years in the rare disease space to help the Company realize its long-term vision.”
Dr. Björn Odlander is Managing Partner and co-founder of HealthCap, a leading European venture capital firm investing in breakthrough therapies for diseases with high unmet medical needs. Dr. Odlander has more than 25 years of experience from the biotech industry and he has been involved in a number of companies that have brought novel therapies for rare diseases to market. He holds a medical degree and a PhD from the Karolinska Institute in Stockholm.
“I was a member of the board of Wilson Therapeutics for two years after the company’s inception. We had already seen back then that WTX101, as a first in class once-daily drug with a unique mechanism of action, had the potential to revolutionize the treatment for this severe disease. Since then the company has continued to evolve exceptionally well so it is very exciting to be back”, said Dr. Björn Odlander.
“Birgitte has a long and successful career in the biopharma industry with an impressive track record in R&D and medical affairs”, said Andrew Kay, Chairman of the Board of Wilson Therapeutics. “Having access to her rare disease focus and extensive experience and leadership will be extremely valuable for the board as we move forward with our development and commercialization plans for WTX101. In addition, Björn is one of the most experienced biotech investors in Europe, also with extensive orphan drug expertise, so we are of course thrilled to welcome them both to the Board.”
About Wilson Therapeutics
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ lead product, WTX101, is in development as a novel treatment for Wilson Disease. A Phase 2 clinical study has been successfully completed and preparations for a pivotal Phase 3 study are ongoing. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.
Visit www.wilsontherapeutics.com for more information.
For further information contact:
Jonas Hansson, CEO, Wilson Therapeutics AB
Telephone: +46 8 796 00 00
Wilson Therapeutics AB (publ)
Org nr 556893-0357
SE-111 43 Stockholm